SGHT
Neutral signalScored 2026-10-06 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Sight Sciences, Inc.
- Nom
- Sight Sciences, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $495.2M
- Employés
- 186
- PDG
- Paul Badawi
- Site web
- https://www.sightsciences.com
- Marché
- ALCBHCGKOSHROWIRIXOCUL
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 37 450 titres (~338 885,05 $ US)
- Insiders
- Badawi DavidBadawi Paul
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$652,777
Avg sell (VWAP, 90d window) $8.95 vs last close $8.47 (-5.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$652,777 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Thin $2,747,029/day · 20d vol
- Last synced
-
2026-10-08 21:10:55
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-02 | Bauerlein Alison | Sell · S · 10b5-1 | 25,260 | $8.85 | $223,627 | Form 4 |
| 2026-10-02 | Rodberg James | Sell · S · 10b5-1 | 7,208 | $8.85 | $63,812 | Form 4 |
| 2026-10-02 | Taylor Brenton | Sell · S · 10b5-1 | 2,988 | $8.85 | $26,453 | Form 4 |
| 2026-10-01 | Badawi David | Sell · S · 10b5-1 | 7,797 | $9.05 | $70,555 | Form 4 |
| 2026-10-01 | Badawi Paul | Sell · S · 10b5-1 | 29,653 | $9.05 | $268,330 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-06 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
SGHT presents a deeply concerning profile combining severe financial distress (persistent negative operating margins, rapid cash burn, deteriorating efficiency) with a weak catalyst score of 25 and no actionable…
The first sentence of the analysis written for SGHT on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $339K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $339K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 10.22 · operating margin -48% — readings disagree
Suggested stop 8.16, nearest stored support minus 0.5 ATR(3.7% under the last close). Reward/risk to the next stored resistance is 1.32. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 86.2% | 85.5% | 85.3% | 82.7% | 82.4% | |
| Ebit Margin | -43.0% | -58.4% | -61.7% | -114.6% | -119.3% | |
| Ebitda Margin | -42.4% | -57.5% | -61.0% | -112.8% | -116.8% | |
| Operating Profit Margin | -48.0% | -63.3% | -70.7% | -117.7% | -105.2% | |
| Pretax Profit Margin | -49.7% | -64.2% | -68.4% | -120.8% | -128.2% | |
| Continuous Operations Profit Margin | -49.7% | -64.5% | -68.5% | -120.9% | -128.6% | |
| Net Profit Margin | -49.7% | -64.5% | -68.5% | -120.9% | -128.6% | |
| Bottom Line Profit Margin | -49.7% | -64.5% | -68.5% | -120.9% | -128.6% | |
| Current Ratio | 10.223 | 9.036 | 13.293 | 11.768 | 20.515 | |
| Quick Ratio | 9.519 | 8.627 | 12.653 | 11.425 | 20.258 | |
| Solvency Ratio | -0.739 | -0.918 | -1.183 | -1.604 | -1.285 | |
| Cash Ratio | 8.340 | 7.781 | 11.274 | 10.383 | 19.304 | |
| Price To Earnings Ratio | -10.716 | -3.534 | -4.526 | -6.783 | -13.211 | |
| Price To Earnings Growth Ratio | 0.381 | 0.366 | 0.123 | -0.192 | -0.166 | |
| Forward Price To Earnings Growth Ratio | 0.381 | 0.366 | 0.123 | -0.192 | -0.166 | |
| Price To Earnings Diluted Ratio | -10.716 | -3.534 | -4.526 | -6.783 | -13.211 | |
| Price To Earnings Diluted Growth Ratio | 0.381 | 0.366 | 0.123 | -0.192 | -0.166 | |
| Price To Book Ratio | 6.467 | 2.085 | 2.087 | 3.650 | 3.596 | |
| Price To Sales Ratio | 5.345 | 2.285 | 3.096 | 8.191 | 17.049 | |
| Price To Free Cash Flow Ratio | -13.822 | -8.026 | -5.230 | -7.594 | -15.644 | |
| Price To Operating Cash Flow Ratio | -13.927 | -8.165 | -5.318 | -7.691 | -15.886 | |
| Debt To Assets Ratio | 0.354 | 0.283 | 0.213 | 0.164 | 0.122 | |
| Debt To Equity Ratio | 0.638 | 0.461 | 0.295 | 0.219 | 0.147 | |
| Debt To Capital Ratio | 0.389 | 0.316 | 0.228 | 0.179 | 0.128 | |
| Long Term Debt To Capital Ratio | 0.387 | 0.310 | 0.209 | 0.172 | 0.123 | |
| Financial Leverage Ratio | 1.803 | 1.632 | 1.386 | 1.331 | 1.207 | |
| Working Capital Turnover Ratio | 0.685 | 0.581 | 0.473 | 0.313 | 0.301 | |
| Operating Cash Flow Ratio | -2.693 | -1.445 | -3.851 | -4.264 | -3.891 | |
| Operating Cash Flow Sales Ratio | -0.384 | -0.280 | -0.582 | -1.065 | -1.073 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | 1.017 | 1.017 | 1.013 | 1.015 | |
| Debt Service Coverage Ratio | -6.378 | -9.896 | -6.493 | -18.030 | -13.145 | |
| Interest Coverage Ratio | -7.215 | -10.839 | -10.591 | -18.798 | -11.791 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -21.264 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.728 | -0.554 | -1.332 | -2.172 | -1.536 | |
| Capital Expenditure Coverage Ratio | -132.562 | -58.055 | -59.651 | -78.314 | -64.625 | |
| Dividend Paid And Capex Coverage Ratio | -132.562 | -58.055 | -59.651 | -78.314 | -64.625 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -11.052 | -2.233 | -2.999 | -5.396 | -10.632 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 86.2% | ▲0.7% | ▲1.8% |
| Ebit Margin | -43.0% | ▲15.3% | ▲36.4% |
| Ebitda Margin | -42.4% | ▲15.1% | ▲35.7% |
| Operating Profit Margin | -47.9% | ▲15.3% | ▲33.0% |
| Pretax Profit Margin | -49.7% | ▲14.5% | ▲36.6% |
| Continuous Operations Profit Margin | -49.7% | ▲14.8% | ▲36.8% |
| Net Profit Margin | -49.7% | ▲14.8% | ▲36.8% |
| Bottom Line Profit Margin | -49.7% | ▲14.8% | ▲36.8% |
| Current Ratio | 10.223 | ▲1.187 | ▼-2.744 |
| Quick Ratio | 9.519 | ▲0.892 | ▼-2.977 |
| Solvency Ratio | -0.739 | ▲0.180 | ▲0.407 |
| Cash Ratio | 8.340 | ▲0.559 | ▼-3.077 |
| Price To Earnings Ratio | -10.716 | ▼-7.182 | ▼-2.962 |
| Price To Earnings Growth Ratio | 0.381 | ▲0.014 | ▲0.278 |
| Forward Price To Earnings Growth Ratio | 0.381 | ▲0.014 | ▲0.278 |
| Price To Earnings Diluted Ratio | -10.716 | ▼-7.182 | ▼-2.962 |
| Price To Earnings Diluted Growth Ratio | 0.381 | ▲0.014 | ▲0.278 |
| Price To Book Ratio | 6.467 | ▲4.382 | ▲2.890 |
| Price To Sales Ratio | 5.345 | ▲3.061 | ▼-1.848 |
| Price To Free Cash Flow Ratio | -13.822 | ▼-5.796 | ▼-3.759 |
| Price To Operating Cash Flow Ratio | -13.927 | ▼-5.762 | ▼-3.729 |
| Debt To Assets Ratio | 0.354 | ▲0.071 | ▲0.127 |
| Debt To Equity Ratio | 0.638 | ▲0.176 | ▲0.286 |
| Debt To Capital Ratio | 0.389 | ▲0.074 | ▲0.141 |
| Long Term Debt To Capital Ratio | 0.387 | ▲0.076 | ▲0.146 |
| Financial Leverage Ratio | 1.803 | ▲0.171 | ▲0.331 |
| Working Capital Turnover Ratio | 0.685 | ▲0.104 | ▲0.214 |
| Operating Cash Flow Ratio | -2.693 | ▼-1.248 | ▲0.536 |
| Operating Cash Flow Sales Ratio | -0.384 | ▼-0.104 | ▲0.293 |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | ▼-0.010 | ▼-0.006 |
| Debt Service Coverage Ratio | -6.378 | ▲3.517 | ▲4.410 |
| Interest Coverage Ratio | -7.215 | ▲3.624 | ▲4.632 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲4.253 |
| Operating Cash Flow Coverage Ratio | -0.728 | ▼-0.174 | ▲0.536 |
| Capital Expenditure Coverage Ratio | -132.562 | ▼-74.508 | ▼-53.921 |
| Dividend Paid And Capex Coverage Ratio | -132.562 | ▼-74.508 | ▼-53.921 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -11.052 | ▼-8.819 | ▼-4.589 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $413.5M | $182.5M | $250.9M | $584.2M | $834.7M | |
| Enterprise value | $362.3M | $102.5M | $148.2M | $434.2M | $608.2M | |
| EV / Sales | 4.68x | 1.28x | 1.83x | 6.09x | 12.42x | |
| EV / Op. cash flow | -12.20x | -4.59x | -3.14x | -5.72x | -11.57x | |
| EV / Free cash flow | -12.11x | -4.51x | -3.09x | -5.64x | -11.40x | |
| EV / EBITDA | -11.05x | -2.23x | -3.00x | -5.40x | -10.63x | |
| Net debt / EBITDA | 1.56x | 1.74x | 2.08x | 1.86x | 3.96x | |
| Current ratio | 10.22x | 9.04x | 13.29x | 11.77x | 20.52x | |
| Income quality | 0.77x | 0.43x | 0.85x | 0.88x | 0.83x | |
| Graham net-net | $1 | $2 | $2 | $3 | $5 | |
| Tax burden | 100.0% | 100.5% | 100.2% | 100.1% | 100.3% | |
| Interest burden | 115.5% | 110.0% | 110.8% | 105.5% | 107.5% | |
| Working capital | $101.7M | $124.3M | $150.6M | $191.9M | $263.5M | |
| Invested capital | $103.8M | $126.8M | $153.7M | $195.0M | $266.5M | |
| Return on assets | -33.3% | -36.1% | -33.3% | -40.5% | -22.5% | |
| Operating ROA | -28.7% | -32.7% | -30.2% | -34.0% | -29.2% | |
| Return on tangible assets | -33.3% | -36.1% | -33.3% | -40.5% | -22.5% | |
| Return on equity | -60.1% | -58.8% | -46.2% | -53.9% | -27.1% | |
| Return on invested capital | -35.4% | -39.5% | -36.4% | -42.8% | -19.3% | |
| Return on capital employed | -35.6% | -39.7% | -37.1% | -43.0% | -19.3% | |
| Earnings yield | -9.3% | -28.2% | -22.1% | -14.8% | -7.5% | |
| Free cash flow yield | -7.2% | -12.5% | -19.1% | -13.2% | -6.4% | |
| Capex / Op. cash flow | -0.8% | -1.7% | -1.7% | -1.3% | -1.5% | |
| Capex / Depreciation | 46.0% | 54.1% | 128.8% | 136.6% | 128.6% | |
| Capex / Sales | 0.3% | 0.5% | 1.0% | 1.4% | 1.7% | |
| SG&A / Sales | 115.2% | 126.2% | 134.3% | 168.3% | 155.6% | |
| R&D / Sales | 18.9% | 22.5% | 21.7% | 32.0% | 31.9% | |
| Stock comp / Sales | 16.9% | 21.4% | 18.0% | 18.2% | 10.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 46d | 49d | 64d | 78d | 65d | |
| Days payables outstanding | 46d | 53d | 53d | 79d | 142d | |
| Operating cycle | 311d | 249d | 305d | 258d | 212d | |
| Cash conversion cycle | 265d | 195d | 252d | 179d | 70d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-01 Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients'' lives, today announced the commercial availability of the OMNI® Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab interno canaloplasty platform. The new technology will be featured at this year''s American Academy of Ophthalmology (AAO) annual meeting held on October 9-12 in New Orleans, Louisiana.
- 2026-09-30 Sight Sciences (NASDAQ:SGHT) Hits New 1-Year High – Should You Buy? Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) hit a new 52-week high during mid-day trading on Monday. The company traded as high as $9.24 and last traded at $9.31, with a volume of 118705 shares trading hands. The stock had previously closed at $8.93. Analyst Ratings Changes A number of research firms have issued
- 2026-09-15 Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-04 BlackRock Inc. Purchases New Shares in Sight Sciences, Inc. $SGHT BlackRock Inc. acquired a new stake in Sight Sciences, Inc. (NASDAQ: SGHT) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,083,108 shares of the company''s stock, valued at approximately $16,710,000. BlackRock Inc. owned approximately 5.67% of Sight Sciences
- 2026-09-01 Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15 MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients'' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
- 2026-08-19 TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients'' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state:
- 2026-08-06 Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
- 2026-08-06 Sight Sciences Q2 Earnings Call Highlights Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.
- 2026-08-06 Sight Sciences Q2 Earnings Call Highlights Sight Sciences (NASDAQ: SGHT) reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance. Total revenue for the quarter ended June 30 was $23.4
- 2026-08-05 Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.